Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Digoxin/furosemide - Cutanea Life Sciences

Drug Profile

Digoxin/furosemide - Cutanea Life Sciences

Alternative Names: CLS-003; Furosemide/digoxin; ICVT; Ionic contra viral therapy

Latest Information Update: 01 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Henderson Morley
  • Developer Cutanea Life Sciences; Henderson Morley
  • Class Antihypertensives; Antivirals; Glycosides; Skin disorder therapies; Small molecules; Sulfanilamides
  • Mechanism of Action Potassium channel antagonists; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Recurrent respiratory papillomatosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Actinic keratosis; Genital warts; Vulvar intraepithelial neoplasia; Warts
  • Discontinued Herpes simplex virus infections; Human papillomavirus infections; Infectious keratoconjunctivitis

Most Recent Events

  • 10 Aug 2018 Phase-II clinical trials in Actinic keratosis (In adults, In the elderly) in Netherlands (Topical) (EudraCT2018-000034-36) (NCT03684772)
  • 24 Jun 2018 Biomarkers information updated
  • 01 Dec 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top